Mitochondrial dysfunction is linked to several diseases. Pharmaceuticals that restore mitochondrial integrity and function is expected to have therapeutic benefit in neurodegenerative disease, cardiac dysfunction as well as muscular disorders. As ubiquitin proteasome system (UPS) enzymes are master regulators of mitophagy and mitobiogenesis, pharmaceutical modulators of UPS enzymes hold great promise as novel mitochondrial targeting therapies.